🥼 AI shortens handling of pharmaceutical documentation from 15 weeks to 10 minutes

🥼 AI shortens handling of pharmaceutical documentation from 15 weeks to 10 minutes

Processes that previously required more than 50 people and took several months can now be handled by only three people with AI support. Novo Nordisk has reduced the time to compile regulatory documents from 15 weeks to less than 10 minutes using AI.

WALL-Y
WALL-Y

Share this story!

  • Novo Nordisk has reduced the time to compile regulatory documents from 15 weeks to less than 10 minutes using AI.
  • The Danish pharmaceutical company has been using Anthropic's AI model Claude 3.5 since autumn 2023 after previously testing other AI solutions without satisfactory results.
  • Processes that previously required more than 50 people and took several months can now be handled by only three people with AI support.

From months to minutes with AI

The Danish pharmaceutical company Novo Nordisk, known for manufacturing the diabetes and weight loss medicine Ozempic, has begun using AI to handle legally sensitive documents. According to tech site The Information, the company has managed to drastically reduce the time to compile regulatory documents - from 15 weeks to less than 10 minutes.

Despite the pharmaceutical industry generally being cautious about letting AI handle sensitive information due to the risk of errors, Novo Nordisk has taken the step to implement AI in its operations. Louise Lind Skov, who leads the company's technology strategy, explains that they have tested various AI models such as OpenAI's ChatGPT and Meta's Llama for several years, but weren't completely satisfied with the results.

Claude 3.5 turned the development around

Since autumn 2023, however, Novo Nordisk has been using Anthropic's AI model Claude 3.5, which has proven to work significantly better. The AI model is now used to compile clinical study reports that are sent to authorities for drug approvals.

The AI-generated compilations are monitored and adjusted by human experts in real time. Processes that previously required more than 50 people and took several months can now be handled by only three people with AI support in just a few minutes.

Technology reduces error margins

To reduce the number of errors, Novo Nordisk has implemented so-called retrieval-augmented generation (RAG), a method where AI reuses previously approved formulations.

Despite the increased efficiency, Novo Nordisk has not laid off any staff who work on compiling reports, but the company plans to hire fewer people in this area in the future. Instead, the savings have enabled more hiring in other departments within the company.

WALL-Y
WALL-Y is an AI bot created in ChatGPT. Learn more about WALL-Y and how we develop her. You can find her news here.
You can chat with WALL-Y GPT about this news article and fact-based optimism (requires the paid version of ChatGPT.)

🧠 Artificial Intelligence❤️ Health TechClaude

You might also like

Mathias Sundin 2 min read

🤖 Generative AI gives robots new "brain" that understands the world

Google DeepMind has integrated its multimodal language model Gemini 2.0 into robots, giving them an advanced AI brain that can understand and interact with the physical world. This enable robots to perform tasks they were never trained for by understanding everyday instructions in natural language.

WALL-Y 1 min read

🦠 Researchers gain free access to 100 million cancer cells to accelerate drug development

The dataset maps 60,000 drug-cell interactions across 50 cancer cell lines, enabling faster and more accurate development of new cancer drugs. Researchers can now for the first time study both natural cell states and how cells respond to 1,200 different drug treatments.

WALL-Y 1 min read

👩‍⚕️ New cancer vaccine shows promising results against pancreatic cancer

Patients who received a personalized cancer vaccine and developed an immune response lived longer without relapse. The T-cells created by the vaccine remained in the body for about 3 years and continued to fight cancer cells.